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Abstract: Here we report novel mutations in ABCA4 with the underlying phenotype in a large French
cohort with autosomal recessive Stargardt disease. The DNA samples of 397 index subjects were
analyzed in exons and flanking intronic regions of ABCA4 (NM_000350.2) by microarray analysis and
direct Sanger sequencing. At the end of the screening, at least two likely pathogenic mutations were
found in 302 patients (76.1%) while 95 remained unsolved: 40 (10.1%) with no variants identified,
52 (13.1%) with one heterozygous mutation, and 3 (0.7%) with at least one variant of uncertain
significance (VUS). Sixty-three novel variants were identified in the cohort. Three of them were
variants of uncertain significance. The other 60 mutations were classified as likely pathogenic or
pathogenic, and were identified in 61 patients (15.4%). The majority of those were missense (55%)
followed by frameshift and nonsense (30%), intronic (11.7%) variants, and in-frame deletions (3.3%).
Only patients with variants never reported in literature were further analyzed herein. Recruited
subjects underwent complete ophthalmic examination including best corrected visual acuity, kinetic
and static perimetry, color vision test, full-field and multifocal electroretinography, color fundus
photography, short-wavelength and near-infrared fundus autofluorescence imaging, and spectral
domain optical coherence tomography. Clinical evaluation of each subject confirms the tendency that
truncating mutations lead to a more severe phenotype with electroretinogram (ERG) impairment
(p = 0.002) and an earlier age of onset (p = 0.037). Our study further expands the mutation spectrum
in the exonic and flanking regions of ABCA4 underlying Stargardt disease.
Keywords: ABCA4; Stargardt disease; phenotype-genotype correlation
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1. Introduction
Stargardt disease-1 (STGD1, Mendelian Inheritance in Man [MIM] 248,200) is a progressive
autosomal recessive macular degeneration linked to pathogenic mutations in ABCA4 (MIM*601,691).
ABCA4 encodes the transmembrane protein ABCA4 (ATP-binding cassette (ABC), subfamily A,
member 4), located in the outer segment disk membranes of cone and rod photoreceptor cells [1–3].
Its loss can lead to the development of several retinal disorders including STGD1, cone and cone-rod
dystrophy, and retinitis pigmentosa [4–11].
Given the large number of variants reported in ABCA4 [12], most of them being polymorphisms,
the identification of true disease-causing mutations is often challenging [5,13,14].
With the advent of new analytical approaches, such as next generation sequencing (NGS),
the detection rates of ABCA4 mutations have greatly increased since its discovery in 1997. Nevertheless,
homozygous or compound heterozygous mutations are regularly detected in no more than 70–75% of
STGD1 patients, while a significant number of patients carry only a single ABCA4 mutation or none at
all [15–19]. On the other hand, several deep intronic variants in non-coding regions were reported to
segregate with STGD1 affecting correct splicing mechanisms [19–23].
Interestingly, all genotyping studies on ABCA4 report a broad mutation spectrum and a high
allelic heterogeneity [6,12,24–26]. This phenomenon may be partially explained by the ethnic variability
of the studied populations [12]. Therefore the need to screen large populations and to identify novel
variants is still relevant [27,28] and can help not only to explore the genetic architecture of ABCA4
pathology, but also the genotype/phenotype correlation. Much effort today is directed towards a more
specific correlation tailored on single variants [24,28–31], even though their low frequency makes it
challenging. Reporting ABCA4 novel variants with a clear and definite correlation with STGD1 would
also help the proper selection of patients for therapeutic clinical trials reaching a higher degree of
confidence with molecular diagnosis [32,33].
To further explore the genetic characteristics of ABCA4 and broaden the spectrum of its pathogenic
variants, we analyzed a large French cohort of 397 STGD1 patients using a combination of microarray
analysis and Sanger sequencing. The purpose of this study was to report all the novel variants identified
evaluating their pathogenicity with in silico analysis. The clinical features were also analyzed and
correlated with the genetic results.
2. Results
Sequencing of ABCA4 in our cohort of 397 STGD1 patients identified a large number of allelic
variants. Microarray technology (ABCR600, ASPER Biotech, Inc., Tartu, Estonia) was used to screen
211 subjects for already known mutations, demonstrating at least two pathogenic variants in 76 of them.
All the unsolved and the remaining cases were addressed to direct Sanger sequencing. At the end of
the screening at least two likely pathogenic mutations were found in 302 patients (76.1%), while 95
remained unsolved: 40 (10.1%) with no variants identified, 52 (13.1%) with one heterozygous mutation,
and 3 (0.7%) with at least one variant of uncertain significance (VUS) (Figure 1).
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2.1. Novel Variants
Sixty-three novel ABCA4 variants were identified in 63 index patients (30 males); 60 variants
(in 61 subjects) were likely pathogenic or pathogenic. The other 3 variants (in 3 subjects) were VUS
(Table 1, uncertain). CIC03678 was a carrier of two novel mutations, one likely pathogenic and
one VUS.
The 60 likely pathogenic or pathogenic variants comprised 33 missense and 6 nonsense variants,
11 deletions, 1 one-base pair (bp) duplication, 1 four-bp duplication, 1 insertion, and 7 variants
presumably affecting splicing (5 single nucleotide substitutions, 1 single-bp deletion, and 1 eight-bp
deletion) (Table 1), which co-segregated with the phenotype in tested available family members.
Table 1. Sixty-three novel variants in patients with Stargardt disease and their classification. Nucleotide
positions and translation correspond to CCDS747.1 and NP_000341.2, respectively.
Exon/Intron Variant Protein Change Classification
1 c.53G>A p.(Arg18Gln) likely pathogenic
IVS5 c.570+1_570+8del p.? pathogenic
6 c.686T>C p.(Leu229Pro) likely pathogenic
IVS7 c.859−2A>G p.? pathogenic
8 c.902del p.(Arg301Serfs*15) pathogenic
8 c.972_973delinsAT p.(Cys324 *) pathogenic
8 c.978C>A p.(Tyr326 *) pathogenic
8 c.1019A>G p.(Tyr340Cys) likely pathogenic
8 c.1050del p.(Ile351Leufs*23) pathogenic
IVS8 c.1099+1G>C p.? pathogenic
9 c.1201A>C p.(Thr401Pro) likely pathogenic
10 c.1252T>C p.(Phe418Leu) likely pathogenic
10 c.1301T>G p.(Val434Gly) likely pathogenic
12 c.1556G>A p.(Cys519Tyr) likely pathogenic
12 c.1648_1659del p.(Gly550_Phe553del) likely pathogenic
12 c.1706A>G p.(Tyr569Cys) likely pathogenic
13 c.1895T>A p.(Ile632Asn) likely pathogenic
14 c.2083G>C p.(Val695Leu) likely pathogenic
15 c.2169_2172dup p.(Leu725Asnfs*42) pathogenic
15 c.2299del p.(Val767Serfs*20) pathogenic
16 c.2443C>T p.(Gln815 *) pathogenic
16 c.2572dup p.(Asp858Glyfs*27) pathogenic
19 c.2868C>A p.(Asn956Lys) uncertain
21 c.3080A>G p.(Tyr1027Cys) likely pathogenic
22 c.3311T>C p.(Leu1104Pro) likely pathogenic
23 c.3409A>G p.(Arg1137Gly) uncertain
25 c.3682G>T p.(Glu1228 *) likely pathogenic
25 c.3811G>C p.(Glu1271Asp) likely pathogenic
26 c.3825G>C p.(Lys1275Asn) likely pathogenic
27 c.3966del p.(Ala1324Argfs*65) pathogenic
27 c.4061A>C p.(His1354Pro) likely pathogenic
IVS27 c.4129−3C>A p.? likely pathogenic
28 c.4178_4192del p.(Val1393_Phe1397del) likely pathogenic
29 c.4324A>G p.(Asn1442Asp) likely pathogenic
30 c.4510_4535del p.(Glu1504Profs*42) pathogenic
32 c.4663_4664del p.(Gln1555Glufs*41) pathogenic
33 c.4689del p.(Gly1564Glufs*17) pathogenic
33 c.4696C>T p.(Leu1566Phe) likely pathogenic
33 c.4700C>T p.(Pro1567Leu) likely pathogenic
34 c.4775G>A p.(Gly1592Asp) likely pathogenic
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Exon/Intron Variant Protein Change Classification
37 c.5282C>G p.(Pro1761Arg) likely pathogenic
38 c.5332A>T p.(Met1778Leu) likely pathogenic
38 c.5342C>A p.(Ala1781Glu) likely pathogenic
38 c.5351T>C p.(Leu1784Pro) likely pathogenic
38 c.5384T>C p.(Leu1795Ser) likely pathogenic
40 c.5621T>C p.(Leu1874Pro) likely pathogenic
IVS42 c.5898+2T>C p.? pathogenic
IVS42 c.5899−3T>C p.? uncertain
43 c.5939C>T p.(Thr1980Ile) likely pathogenic
IVS43 c.6005+1del p.? pathogenic
44 c.6110C>A p.(Ala2037Asp) likely pathogenic
45 c.6181_6184del p.(Thr2061Serfs*53) pathogenic
45 c.6191C>T p.(Ala2064Val) likely pathogenic
45 c.6250G>A p.(Ala2084Thr) likely pathogenic
46 c.6284A>G p.(Asp2095Gly) likely pathogenic
47 c.6394G>T p.(Glu2132 *) pathogenic
47 c.6454G>A p.(Gly2152Ser) likely pathogenic
47 c.6455G>T p.(Gly2152Val) likely pathogenic
47 c.6436_6437insT p.(Gly2146Valfs*36) pathogenic
48 c.6693del p.(Ile2231Metfs*16) pathogenic
48 c.6704C>G p.(Ser2235 *) pathogenic
49 c.6746C>A p.(Ala2249Asp) likely pathogenic
IVS49 c.6816+1G>T p.? pathogenic
p.?: Protein has not been analysed, an effect is expected but difficult to predict.
Co-segregation analysis allowed the identification of complex alleles with in cis mutations in
18 patients. Nine additional patients had more than two variations, but it was impossible to establish
phase and determine each allele due to the lack of DNA from additional family members.
All genotypic information about patients and co-segregation analysis are reported in Table 2.
Four missense mutations (i.e., p.(Cys519Tyr), p.(Glu1271Gln), p.(Gly1592Asp), and p.(Asp2095Gly))
were analyzed also with the splicing predictor tools due to their proximity with a putative splice site. None
of them was predicted to affect splicing significantly but they were predicted as disease-causing by the
missense prediction in silico algorithms.
Among all novel mutations, p.(Tyr340Cys), p.(Val434Gly), and p.(Gly2146Valfs*36) were found at
a homozygous state (Table 2).
CIC08932 inherited the complex allele p.(Asn96Lys; Gly1961Glu) from the unaffected mother, but
the novel variant p.(Gly1592Asp) was not found in the unaffected father (Table 2). This variant could
be de novo in the index patient or CIC08933 may not be the biological father. Unfortunately, it was
impossible to get this information from the subject, and our informed consent did not cover single
nucleotide polymorphisms analysis for paternity testing.
Three novel variants found in three index patients (p.(Asn956Lys), p.(Arg1137Gly), and
c.5899−3T>C) were considered VUS. Conservation and pathogenic prediction data for each variant
are reported in Supplementary Tables S1 and S2.
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Table 2. Sixty novel likely pathogenic mutations in 61 index patients with Stargardt disease and cosegregation analysis. Nucleotide positions and translation
correspond to CCDS747.1 and NP_000341.2, respectively.
Allele 1 Allele 2 Allele 1 or 2









CIC03734 1673 Index 1 c.53G>A p.(Arg18Gln) 42 c.5882G>A [25] p.(Gly1961Glu)
CIC03735 1673 Affectedbrother 1 c.53G>A p.(Arg18Gln) 42 c.5882G>A [25] p.(Gly1961Glu)
CIC06131 1673 Unaffectedfather 1 c.53G>A p.(Arg18Gln) WILD TYPE
CIC06908 3783 Index IVS5 c.570+1_570+8del p.? 40 c.5603A>T [34] p.(Asn1868Ile)
45 c.6148G>C [25] p.(Val2050Leu)
CIC08771 3783 Unaffectedmother WILD TYPE 40 c.5603A>T [34] p.(Asn1868Ile)
CIC08774 3783 Unaffectedbrother IVS5 c.570+1_570+8del - WILD TYPE
45 c.6148G>C [25] p.(Val2050Leu)
CIC07895 4412 Index 6 c.686T>C p.(Leu229Pro) 24 c.3602T>G [5] p.(Leu1201Arg)
40 c.5621T>C p.(Leu1874Pro)
CIC07896 4412 Unaffectedmother 6 c.686T>C p.(Leu229Pro) WILD TYPE
CIC07887 4407 Index 6 c.686T>C p.(Leu229Pro) 42 c.5882G>A [25] p.(Gly1961Glu)
48 c.6529G>A [35] p.(Asp2177Asn)
CIC07888 4407 Unaffectedmother 6 c.686T>C p.(Leu229Pro) WILD TYPE
48 c.6529G>A [35] p.(Asp2177Asn)
CIC09848 5658 Index IVS7 c.859−2A>G - 8 c.872C>T [36] p.(Pro291Leu)
11 c.1531C>T [18] p.(Arg511Cys)
CIC09849 5658 Unaffectedmother WILD TYPE 8 c.872C>T [37] p.(Pro291Leu)
11 c.1531C>T [18] p.(Arg511Cys)
CIC09382 5385 Index 8 c.978C>A p.(Tyr326 *) IVS42 c.5898+2T>C p.?
CIC06749 3669 Index 8 c.902del p.(Arg301Serfs*15) 46 c.6320G>A [26] p.(Arg2107His)
Int. J. Mol. Sci. 2018, 19, 2196 6 of 27
Table 2. Cont.
CIC06088 3203 Index 8 c.972_973delinsAT p.(Cys324 *) 23 c.3386G>T [38] p.(Arg1129Leu)
CIC08477 3203 Unaffectedfather 8 c.972_973delinsAT p.(Cys324 *) WILD TYPE
CIC08478 3203 Unaffectedmother WILD TYPE 23 c.3386G>T [38] p.(Arg1129Leu)
CIC07725 4301 Index 8 c.1019A>G p.(Tyr340Cys) 8 c.1019A>G p.(Tyr340Cys)
CIC07726 4301 Unaffectedfather 8 c.1019A>G p.(Tyr340Cys) WILD TYPE
CICO7727 4301 Unaffectedmother WILD TYPE 8 c.1019A>G p.(Tyr340Cys)
CIC04235 2021 Index 8 c.1050del p.(Ile351Leufs*23) 38 c.5351T>C p.(Leu1784Pro)
CIC04236 2021 Unaffectedsister 8 c.1050del p.(Ile351Leufs*23) WILD TYPE
CIC07308 4026 Index 8 c.1050del p.(Ile351Leufs*23) 42 c.5882G>A [25] p.(Gly1961Glu)
CIC01080 659 Index 8 c.1050del p.(Ile351Leufs*23) 19 c.2819C>G [39] p.(Pro940Arg)
23 c.3364G>A [6] p.(Glu1122Lys)
CIC03521 659 Unaffectedmother WILD TYPE 19 c.2819C>G [39] p.(Pro940Arg)
23 c.3364G>A [6] p.(Glu1122Lys)
CIC03524 659 Unaffectedsister WILD TYPE WILD TYPE
CIC08372 4715 Index IVS8 c.1099+1G>C p.? 22 c.3322C>T [26] p.(Arg1108Cys)
CIC05266 2672 Index 9 c.1201A>C p.(Thr401Pro) 17 c.2588G>C [25] p.(Gly863Ala)
40 c.5603A>T [34] p.(Asn1868Ile)
CIC05267 2672 Unaffectedmother 9 c.1201A>C p.(Thr401Pro) WILD TYPE
CIC05268 2672 Unaffectedfather WILD TYPE 17 c.2588G>C [25] p.(Gly863Ala)
40 c.5603A>T [34] p.(Asn1868Ile)
CIC02804 1037 Index 10 c.1252T>C p.(Phe418Leu) IVS43 c.6005+1del p.? 42 c.5882G>A [25] p.(Gly1961Glu)
CIC09625 5521 Index 10 c.1301T>G p.(Val434Gly) 10 c.1301T>G p.(Val434Gly)
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CIC09624 5521 Affectedbrother 10 c.1301T>G p.(Val434Gly) 10 c.1301T>G p.(Val434Gly)
CIC09626 5521 Unaffectedfather 10 c.1301T>G p.(Val434Gly) WILD TYPE
CIC09628 5521 Unaffectedmother WILD TYPE 10 c.1301T>G p.(Val434Gly)
CIC01301 784 Index 12 c.1556G>A p.(Cys519Tyr) 22 c.3292C>T [40] p.(Arg1098Cys)
CIC09999 784 Affectedbrother 12 c.1556G>A p.(Cys519Tyr) 22 c.3292C>T [41] p.(Arg1098Cys)
CIC06346 3356 Index 12 c.1648_1659del p.(Gly550_Phe553del) 42 c.5882G>A [25] p.(Gly1961Glu)
CIC08884 3356 Unaffectedfather 12 c.1648_1659del p.(Gly550_Phe553del) WILD TYPE
CIC08949 3356 Unaffectedmother WILD TYPE 42 c.5882G>A [25] p.(Gly1961Glu)
CIC04197 1992 Index 12 c.1706A>G p.(Tyr569Cys) 40 c.5603A>T [34] p.(Asn1868Ile)
CIC07749 4314 Index 13 c.1895T>A p.(Ile632Asn) 33 c.4700C>T p.(Pro1567Leu) 24 c.3602T>G [5] p.(Leu1201Arg)
CIC08724 4948 Index 14 c.2083G>C p.(Val695Leu) 47 c.6445C>T [6] p.(Arg2149*)
44 c.6079C>T [29] p.(Leu2027Phe)
CIC08723 4948 Affectedsister 14 c.2083G>C p.(Val695Leu) 47 c.6445C>T [6]
p.(Arg2149
*)
44 c.6079C>T [29] p.(Leu2027Phe)
CIC08858 4948 Unaffectedmother 14 c.2083G>C p.(Val695Leu) WILD TYPE
44 c.6079C>T [29] p.(Leu2027Phe)
CIC08859 4948 Unaffectedfather WILD TYPE 47 c.6445C>T [6]
p.(Arg2149
*)
CIC07985 4793 Index 15 c.2169_2172dup p.(Leu725Asnfs*42) 47 c.6454G>A p.(Gly2152Ser) 44 c.6079C>T [25] p.(Leu2027Phe)
40 c.5603A>T [34] p.(Asn1868Ile)
CIC06126 3227 Index 15 c.2299del p.(Val767Serfs*20) 17 c.2588G>C [25] p.(Gly863Ala) 40 c.5603A>T [34] p.(Asn1868Ile)
CIC09405 5401 Index 16 c.2443C>T p.(Gln815 *) 42 c.5882G>A [25] p.(Gly1961Glu)
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CIC09407 5401 Unaffectedmother WILD TYPE 42 c.5882G>A [25] p.(Gly1961Glu)
CIC09408 5401 Unaffectedfather 16 c.2443C>T p.(Gln815 *) WILD TYPE
CIC00467 319 Index 16 c.2572dup p.(Asp858Glyfs*27) 35 c.4926C>G [42] p.(Ser1642Arg)
36 c.5044_5058del[25] p.(Val1682_Val1686del)
CIC05014 319 Unaffectedsister 16 c.2572dup p.(Asp858Glyfs*27) WILD TYPE
CIC05056 319 Affectedbrother 16 c.2572dup p.(Asp858Glyfs*27) 35 c.4926C>G [43] p.(Ser1642Arg)
36 c.5044_5058del[25] p.(Val1682_Val1686del)
+ CIC03678 1627 Index 19 c.2868C>A p.(Asn956Lys) 43 c.5939C>T p.(Thr1980Ile)
CIC03679 1627 Unaffectedson WILD TYPE 43 c.5939C>T p.(Thr1980Ile)
CIC04259 2036 Index 21 c.3080A>G p.(Tyr1027Cys) 38 c.5381C>A [24] p.(Ala1794Asp)
CIC08538 4826 Index 22 c.3311T>C p.(Leu1104Pro) IVS49 c.6816+1G>A[6] -
CIC04176 1973 Index 25 c.3682G>T p.(Glu1228*) 22 c.3322C>T [26] p.(Arg1108Cys)
CIC02505 871 Index 25 c.3811G>C p.(Glu1271Gln) 23 c.3386G>T [38] p.(Arg1129Leu)
CIC05899 3087 Index 25 c.3811G>C p.(Glu1271Gln) 42 c.5882G>A [25] p.(Gly1961Glu)
CIC07120 3909 Index 26 c.3825G>C p.(Lys1275Asn) 22 c.3322C>T [26] p.(Arg1108Cys) 40 c.5603A>T [34] p.(Asn1868Ile)
46 c.6320G>A [26] p.(Arg2107His)
CIC01750 1242 Index 27 c.3966del p.(Ala1324Argfs*65) 35 c.4918C>T [26] p.(Arg1640Trp)
40 c.5603A>T [34] p.(Asn1868Ile)
CIC02024 1242 Affectedsister 27 c.3966del p.(Ala1324Argfs*65) 35 c.4918C>T [26] p.(Arg1640Trp)
40 c.5603A>T [34] p.(Asn1868Ile)
CIC07100 1242 Unaffectedfather WILD TYPE 35 c.4918C>T [26] p.(Arg1640Trp)
40 c.5603A>T [34] p.(Asn1868Ile)
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CIC07146 1242 Unaffectedmother 27 c.3966del p.(Ala1324Argfs*65) WILD TYPE
CIC07744 4372 Index 27 c.4061A>C p.(His1354Pro) 13 c.1927G>A [44] p.(Val643Met) 8 c.872C>T [37] p.(Pro291Leu)
24 c.3602T>G [6] p.(Leu1201Arg)
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40 c.5603A>T [34] p.(Asn1868Ile)
CIC08194 4588 Index 28 c.4178_4192del p.(Val1393_Phe1397del) 40 c.5603A>T [34] p.(Asn1868Ile) 45 c.6148G>C [25] p.(Val2050Leu)
CIC07994 4463 Index 29 c.4324A>G p.(Asn1442Asp) 3 c.194G>A [46] p.(Gly65Glu)
CIC07998 4463 Unaffectedmother WILD TYPE 3 c.194G>A [46] p.(Gly65Glu)
CIC06727 3652 Index 30 c.4510_4535del p.(Glu1504Profs*42) 28 c.4139C>T [6] p.(Pro1380Leu)
CIC06728 3652 Unaffectedfather WILD TYPE 28 c.4139C>T [6] p.(Pro1380Leu)
CIC06729 3652 Unaffectedbrother WILD TYPE 28 c.4139C>T [6] p.(Pro1380Leu)
CIC06730 3652 Unaffectedmother 30 c.4510_4535del p.(Glu1504Profs*42) WILD TYPE
CIC08283 4647 Index 32 c.4663_4664del p.(Gln1555Glufs*41) 40 c.5603A>T [34] p.(Asn1868Ile)
CIC03252 1375 Index 33 c.4689del p.(Gly1564Glufs*17) 17 c.2588G>C [25] p.(Gly863Ala)
40 c.5603A>T [34] p.(Asn1868Ile)
CIC03253 1375 Unaffectedmother WILD TYPE 17 c.2588G>C [25] p.(Gly863Ala)
40 c.5603A>T [34] p.(Asn1868Ile)
CIC09219 5282 Index 33 c.4696C>T p.(Leu1566Phe) 21 c.3056C>T [26] p.(Thr1019Met)
42 c.5882G>A [25] p.(Gly1961Glu)
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CIC10754 5282 Unaffectedmother WILD TYPE 21 c.3056C>T [26] p.(Thr1019Met)
CIC10755 5282 Unaffectedfather 33 c.4696C>T p.(Leu1566Phe) WILD TYPE
42 c.5882G>A [25] p.(Gly1961Glu)
CIC08932 5089 Index 34 c.4775G>A p.(Gly1592Asp) 3 c.288C>A [47] p.(Asn96Lys)
42 c.5882G>A [25] p.(Gly1961Glu)
++ CIC08933 5089 Unaffectedfather WILD TYPE WILD TYPE
CIC08934 5089 Unaffectedmother WILD TYPE 3 c.288C>A [47] p.(Asn96Lys)
42 c.5882G>A [25] p.(Gly1961Glu)
CIC07036 3867 Index 37 c.5282C>G p.(Pro1761Arg) 42 c.5882G>A [25] p.(Gly1961Glu)
CIC07960 4447 Index 37 c.5282C>G p.(Pro1761Arg) 26 c.3819dup [48] p.(Leu1274Serfs*8)
46 c.6316C>T [25] p.(Arg2106Cys)
CIC07999 4447 Unaffectedsister WILD TYPE WILD TYPE
CIC08029 4447 Unaffectedmother 37 c.5282C>G p.(Pro1761Arg) WILD TYPE
46 c.6316C>T [25] p.(Arg2106Cys)
CIC09601 5509 Index 37 c.5282C>G p.(Pro1761Arg) 22 c.3279C>A [18] p.(Asp1093Glu)
46 c.6316C>T [25] p.(Arg2106Cys)
CIC09602 5509 Unaffecteddaughter 37 c.5282C>G p.(Pro1761Arg) WILD TYPE
46 c.6316C>T [25] p.(Arg2106Cys)
CIC07831 4373 Index 38 c.5332A>T p.(Met1778Leu) 27 c.3899G>A [44] p.(Arg1300Gln)
CIC08439 4759 Index 38 c.5332A>T p.(Met1778Leu) 47 c.6394G>T p.(Glu2132*)
CIC08262 4633 Index 38 c.5342C>A p.(Ala1781Glu) 3 c.286A>G [49] p.(Asn96Asp)
CIC08263 4633 Unaffectedmother 38 c.5342C>A p.(Ala1781Glu) WILD TYPE
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CIC09095 4633 Unaffectedfather WILD TYPE 3 c.286A>G [49] p.(Asn96Asp)
CIC08359 4702 Index 38 c.5384T>C p.(Leu1795Ser) 17 c.2588G>C [25] p.(Gly863Ala) 40 c.5603A>T [34] p.(Asn1868Ile)
CIC07436 4110 Index IVS42 c.5898+2T>C p.? 40 c.5642C>T [50] p.(Ala1881Val)
CIC08523 4110 Unaffectedmother WILD TYPE 40 c.5642C>T [50] p.(Ala1881Val)
CIC08524 4110 Unaffectedfather IVS42 c.5898+2T>C p.? WILD TYPE




40 c.5603A>T [34] p.(Asn1868Ile)
CIC09858 5675 Unaffectedmother 44 c.6110C>A p.(Ala2037Asp) WILD TYPE






40 c.5603A>T [34] p.(Asn1868Ile)
CIC01199 719 Index 45 c.6181_6184del p.(Thr2061Serfs*53) 42 c.5882G>A [25] p.(Gly1961Glu)
CIC08054 719 Affectedsister 45 c.6181_6184del p.(Thr2061Serfs*53) 42 c.5882G>A [25] p.(Gly1961Glu)
CIC08057 719 Unaffectedfather WILD TYPE 42 c.5882G>A [25] p.(Gly1961Glu)
CIC8058 719 Unaffectedmother 45 c.6181_6184del p.(Thr2061Serfs*53) WILD TYPE
CIC03710 1657 Index 45 c.6191C>T p.(Ala2064Val) 30 c.4537dup [44] p.(Gln1513Profs*42)
40 c.5603A>T [34] p.(Asn1868Ile)
CIC03711 1657 Unaffectedmother 45 c.6191C>T p.(Ala2064Val) WILD TYPE
40 c.5603A>T [34] p.(Asn1868Ile)
CIC04571 2232 Index 45 c.6250G>A p.(Ala2084Thr) 19 c.2894A>G [25] p.(Asn965Ser)
42 c.5882G>A [25] p.(Gly1961Glu)
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WILD TYPE 19 c.2894A>G [25] p.(Asn965Ser)
CIC07568 2232 Unaffectedfather 45 c.6250G>A p.(Ala2084Thr) WILD TYPE
42 c.5882G>A [25] p.(Gly1961Glu)
CIC07748 4312 Index 46 c.6284A>G p.(Asp2095Gly) 22 c.3323G>A [34] p.(Arg1108His)
CIC09593 4312 Unaffectedmother 46 c.6284A>G p.(Asp2095Gly) WILD TYPE
CIC09594 4312 Unaffectedfather WILD TYPE 22 c.3323G>A [34] p.(Arg1108His)
CIC09374 5379 Index 47 c.6455G>T p.(Gly2152Val) 9 c.1222C>T [43] p.(Arg408*)
CIC09375 5379 Unaffectedmother 47 c.6455G>T p.(Gly2152Val) WILD TYPE
CIC06396 3389 Index 47 c.6436_6437insT p.(Gly2146Valfs*36) 47 c.6436_6437insT p.(Gly2146Valfs*36)
CIC00130 102 Index 48 c.6693del p.(Ile2231Metfs*16) 44 c.6079C>T [25] p.(Leu2027Phe)
CIC00131 102 Unaffectedfather 48 c.6693del p.(Ile2231Metfs*16) WILD TYPE
CIC00132 102 Unaffectedmother WILD TYPE 44 c.6079C>T [25] p.(Leu2027Phe)
CIC09114 5205 Index 48 c.6704C>G p.(Ser2235 *) 21 c.3113C>T [24] p.(Ala1038Val)
CIC08581 4855 Index 49 c.6746C>A p.(Ala2249Asp) 13 c.1819G>A [40] p.(Gly607Arg) 42 c.5882G>A [25] p.(Gly1961Glu)
CIC08381 4722 Index IVS49 c.6816+1G>T p.? 14 c.2023G>A [38] p.(Val675Ile)
CIC08383 4722 Affectedsister IVS49 c.6816+1G>T p.? 14 c.2023G>A [38] p.(Val675Ile)
CIC08402 4722 Unaffectedmother WILD TYPE 14 c.2023G>A [38] p.(Val675Ile)
+: CIC03678 is carrier of a variant of uncertain significance (c.2868C>A), and hence was excluded from genotype-phenotype analysis. ++: CIC08933, unaffected father of CIC08932 does not
carry any likely pathogenic variant therefore variant c.4775G>A could be de novo or CIC08933 is not the biological father of CIC08932. p.?: Protein has not been analysed, an effect is
expected but difficult to predict.
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All novel variants found in the study and their respective position on ABCA4 are represented in
Figure 2.
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2.2. Genotype-Phenotype Correlation
Genotype-phenotype correlation analysis was performed on the 60 patients carrying at least one
likely pathogenic variant on each allele. The three subjects carrying a VUS were excluded from the
anal sis. All clinical features are presented in the Supplementar Table S3.
Patients were divided in two genotype groups: (1) patients with at least one null mutation (NM),
i.e., frame-shift or nonsense mutatio s, splicing variants affecting the first tw nucleotides adjacent to
an exonic sequence and/or other variants roven to cause a premature stop or incomplete formation of
the whole protein in previous studies (e.g., c.5461−10T>C [51]); (2) patients with two or more missense
variants (MM) [52].
The two genotypic groups were not statistically different for age (mean of 34.3 ± 17.8 years for NM
group and 33.9 ± 18.3 years for MM group; p = 0.94) nor duration of disease (mean of 16.9 ± 14.6 years
for NM group and 10.8 ± 10.9 years for MM group; p = 0.095).
Mean age of onset was 18.5 ± 12.59 years and 23.1 ± 14.8 years in NM and MM groups,
respectively (p = 0.037).
Right eye (RE) and left eye (LE) did not differ significantly for best corrected visual acuity (BCVA)
(p = 0.81), central retinal thickness (CRT) (p = 0.09), and macular volume (MV) (p = 0.137), therefore we
chose to use data from the right eye for comparison between genotypic groups.
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Null mutation and MM groups did not differ significantly for optical coherence tomography
(OCT) parameters: mean CRT was 126.7 ± 45.3 µm and 122 ± 26.1 µm, respectively (p = 0.89), while
mean MV was 6.2 ± 1.3 mm2 and 6.8 ± 1.1 mm2, respectively (p = 0.13 for MV). Mean BCVA was
0.97 ± 0.48 logMAR in the NM group and 0.85 ± 0.29 logMAR in the MM group (p = 0.26) (Figure 3).
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at least one null mutation (NM) and patients with two or more missense variants (MM)). The dark 
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The phenotype was classified following all clinical criteria summarized in Table 3. 
Figure 3. Box-plots showing the comparison of age of onset (AO), best corrected visual acuity (BCVA),
central retinal thickness (CRT), and macular volume (MV) for the two genotype groups (patients with
at least one null mutation (NM) and patients with two or more missense variants (MM)). The dark
line in the middle of the boxes is the median; the bottom of the box indicates the 25th percentile while
the top of the box represents the 75th percentile. The T-bars that extend from the boxes represent the
minimum and maximum values when they are within 1.5 times the height of the box. The circles
are outliers (i.e., values that do not fall in the T-bars). The stars are extreme outliers (i.e., values
more than three times the height of the boxes). Only AO shows a statistically significant difference
between NM and MM.
The phenotype was classified following all clinical criteria summarized in Table 3.
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Table 3. Clinical criteria used to classify patients in our study. FP: fundus photography; SW-AF: short-wavelength fundus autofluorescence; NIR-AF: near-infrared
fundus autofluorescence; ERG: electroretinogram; OCT: optical coherence tomography; RPE: retinal pigment epithelium; EZ: ellipsoid zone; FS: foveal sparing.
Groups/Stages Criteria Reference
Age of onset n.a. Age at which visual loss was first noticed Lois et al., 2001 [53]
FP
Stage 1 Central macular atrophy with parafoveal or perifoveal flecks Fishman GA et al., 1976 [54]
Stage 2 Numerous flecks extended anterior to the vascular arcades and/or nasal to the optic disc
Stage 3 Desorbed flecks with choriocapillaris atrophy within the macula
Stage 4 Widespread RPE and chorioretinal atrophy throughout the fundus defined stage
SW-AF and NIR-AF
Group 1 Central lesion with jagged border Duncker et al., 2014 [55]
Group 2 Lesion with extensive fundus changes
Group 3 Central lesion with smooth border and hyperautofluorescent SW-AF and NIR-AF ring
Group 4 Central lesion with smooth border and no hyperautofluorescent NIR-AF ring
Group 5 Discrete central lesions better visualized in NIR-AF images
Peripapillary area preserved No alterations within an eccentricity of 0.6 mm from the optic disc Cideciyan et al., 2005 [56]
Flecks in the peripapillary area Presence of flecks within an eccentricity of 0.6 mm from the optic disc
Peripapillary area not preserved Absence of EZ band and/or EPR atrophy within an eccentricity of 0.6 mm from the optic disc
ERG
I Normal scotopic and full-field ERG Lois et al., 2001 [53]
II Loss of photopic function
III Loss of both photopic and scotopic function
SW-AF and OCT
FS-YES Foveal sparing Fujinami et al., 2013 [38]
FS-NO Early onset foveal atrophy
OCT
EZ Absent EZ band loss Parodi et al., 2015 [57]
EZ Disrupted EZ band disorganization
EZ Preserved Identification of EZ band
Genotype NM At least one null or splice variant is present Fujinami et al., 2013 [52]
MM Two or more missense variants are present
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Fundus staging, short-wavelength fundus autofluorescence (SW-FAF), and near infrared fundus
autofluorescence (IR-FAF) groups, foveal sparing, the presence of retinal pigment epithelium (RPE)
atrophy and the integrity of the ellipsoid zone (EZ) band were not statistically different between the
NM and MM groups (p = 0.315, p = 0.855, p = 0.441, p = 0.327, p = 0.089, respectively). However,
electroretinogram (ERG) group distribution and the presence of autofluorescence peripapillary sparing
significantly differed between the two groups (p = 0.002 and p = 0.003 respectively) (Figure 4).
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patients with at least one null mutation. 
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sequencing on the entire cohort. Initially, patients were analyzed with microarray to evaluate the 
prevalence of known mutations, which was at this time commonly used to reduce screening costs. 
However, the high number of unsolved cases led us to further investigate the cohort with direct 
Sanger sequencing. The sole application of microarray was enough to solve 76 cases, which were not 
further investigated with Sanger technique. Indeed, this may have led to an underestimation of the 
prevalence of novel additional mutations and/or complex alleles in this cohort [28,58]. The relatively 
high number of unsolved cases may be related to a combination of different factors: (1) The clinical 
overlap of distinct genetic entities could have led to uncertainties in patients’ selection. Therefore the 
screening of other genes (e.g., ELOVL4, PROM1, PRPH2, etc.) responsible for overlapping phenotypes 
may help solving such cases; (2) Large rearrangements within the ABCA4 locus have been shown to 
occur in ~0.5% to ~2% of STGD1 cases in previous reports and they would not have been detected by 
our mutational screening [22,24]; (3) Mutations in noncoding regions of the ABCA4 gene locus have 
been proposed as a common source for a second causative mutation in patients with typical Stargardt 
phenotype. In particular, the occurrence of deep intronic variants in subjects with a single ABCA4 
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Figure 4. Repartition between the two genotypic subtypes for electroretinography (ERG) groups
(on the left) and peripapillary sparing (on the right). For ERG classification, group I has abnormal
multifocal (mf-) ERG with normal full-field (ff-) ERG; in group II there were mf-ERG abnormalities
with cone dysfunction (assessed with light-adapted 30 Hz flicker and light-adapted 3.0); Group III has
additional rod dysfunction (assessed using dark-adapted 0.01 and dark-adapted 10.0). Peripapillary
area was considered speared (Yes in the graph) if no alterations were found in the fundus
autofluorescence within 0.6 mm from the optic disc edge. This area was not considered speared
when flecks or ellipsoid zone (EZ) and/or retinal pigment epithelium (RPE) atrophy were present
(see Table 3 for classifications). Photoreceptors dysfunction (ERG groups II and III) and peripapillary
area involved with the presence of flecks or atrophy are more prevalent in the group of patients with at
least one null mutation.
3. Discussion
This work is a longitudinal study starting in 2007 which used a combination of microarray analysis
and direct Sanger sequencing to identify ABCA4 mutations in a large French cohort with a clinical
diagnosis of STGD1 disease. At that time targeted NGS and whole exome sequencing (WES) was
not available in our laboratory. The rate of bi-allelic variants detected in the population using this
approach was 75.6%, which is in accordance with previously reported data (about 75%) [15–19].
The authors believe that the same results would have been obtained using only direct Sanger
sequencing on the entire cohort. Initially, patients were analyzed with microarray to evaluate the
prevalence of known mutations, which was at this time commonly used to reduce screening costs.
However, the high number of unsolved cases led us to further investigate the cohort with direct
Sanger sequencing. The sole application of microarray was enough to solve 76 cases, which were not
further investigated with Sanger technique. Indeed, this may have led to an underestimation of the
prevalence of novel additional mutations and/or complex alleles in this cohort [28,58]. The relatively
high number of unsolved cases may be related to a combination of different factors: (1) The clinical
overlap of distinct genetic entities could have led to uncertainties in patients’ selection. Therefore the
screening of other genes (e.g., ELOVL4, PROM1, PRPH2, etc.) responsible for overlapping phenotypes
may help solving such cases; (2) Large rearrangements within the ABCA4 locus have been shown to
occur in ~0.5% to ~2% of STGD1 cases in previous reports and they would not have been detected by
our mutational screening [22,24]; (3) Mutations in noncoding regions of the ABCA4 gene locus have
been proposed as a common source for a second causative mutation in patients with typical Stargardt
phenotype. In particular, the occurrence of deep intronic variants in subjects with a single ABCA4
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mutations may range from ~2% to ~18% in different reports [19–22,27,59]. This may have led not
only to an underestimation of bi-allelic cases, but also of the number of novel variants found in the
cohort, whose report was the main aim of this study. However, the number of novel variants affecting
deep intronic regions should be relatively small. Schulz et al. [27] in a recent report screened for deep
intronic variants 237 STGD1 patients showing a single ABCA4 variant. Among the cohort, ten different
sequence variants were found, only two of which were not previously reported [27]. The addition of
the first, the screening of selected noncoding regions known to be “hot spots” for pathogenic variants
(e.g., intron 30 and 36 [27]), and second, whole genome sequencing (WGS) analysis, will be the next
steps in order to raise the number of solved cases in our cohort.
Among the 305 patients with bi-allelic variants, we found a total of 240 disease-causing mutations,
of which 60 (25%) were never described before (Table 2).
The high number of new variants found in this cohort may seem surprising considering that several
studies had already been conducted on the western and central European populations [5,15,17,27,43].
These findings are probably related to the extensive allelic heterogeneity of ABCA4 and the possible
contribution of ethnic differences [12]. Among the 61 patients with novel likely pathogenic or pathogenic
variants, three subjects had eastern European origins and nine subjects had non-European origins.
The novel variant p.(Pro1761Arg) is carried by three subjects with no ties of consanguinity and with
non-European origins: Armenia (CIC07960), Turkey (CIC09601), and Algeria (CIC07036). This may suggest
a higher prevalence of this mutation in the south Mediterranean area. Both CIC07960 and CIC09601 harbor
the variant in cis with p.(Arg2106Cys). Interestingly, the two subjects share the same pattern distribution of
the lesion, but CIC07960 has an earlier age of onset and an important foveal involvement, probably due to
the associated truncating mutation p.(Leu1274Serfs*8) (Figure 5).
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Figure 5. Near infrared autofluorescence (SW-AF) of subjects CIC09601 (A) and CIC07960 (B).
The novel variant p.(Ile351Leufs*23) was carried by three unrelated French subjects indicating
a possible higher prevalence in this population. While CIC01080 and CIC04235 share an early onset
Int. J. Mol. Sci. 2018, 19, 2196 18 of 27
advanced disease with spread fundus atrophy, CIC07308 has a normal ff-ERG and no posterior atrophy
probably due to the second mutation p.(Gly1961Glu), known for its “milder” pathologic effect [30,31].
Among the likely pathogenic novel variants three were homozygous: p.(Tyr340Cys), p.(Val434Gly),
and p.(Gly2146Valfs*36).
CIC07725, harboring p.(Tyr340Cys), had early-onset disease (nine years of age) with normal ff-ERG,
centripetal spread of flecks and foveal EZ band involvement. CIC09625, harboring p.(Val434Gly) has an
early onset disease (nine years of age) with a central lesion without flecks and with foveal sparing. Even
though they share a similar age of onset and duration of the disease (one and two years, respectively),
CIC09625 shows a “milder” phenotype (Figure 6). These two missense mutations may have a distinct
impact on the protein function even though they are located in the same domain (first ABCA4 extracellular
domain). Alternatively, genetic or environmental modifiers may explain the phenotypic variability.
As expected, CIC06396, homozygous for p.(Gly2146Valfs*36), showed a more advanced
phenotype with an early onset disease (nine years of age), extensive fundus RPE atrophy and
photoreceptor impairment (Figure 6).
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VUS identified in the cohort were two missense variants: p.(Asn956Lys), p.(Arg1137Gly), and one
non-canonical splice-site variant (c.5899−3T>C) (Table 1 and Supplementary Table S2).
CIC05824 harbors the novel intronic variant c.5899−3T>C, which is not predicted to
affect splicing by the algorithms used since the nucleotide is poorly evolutionarily conserved
(Supplementary Table S2). Indeed, we cannot exclude the possibility that this variant may affect
splicing in vivo since it has already been proven that ABCA4 can have non-canonical splice sites
variant with important effects on protein [19–23,59].
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The VUS p.(Asn956Lys) harbored by CIC03678 is predicted to be pathogenic only by SIFT and
the AA is not conserved (Table 1, Supplementary Table S2). Asparagine and Lysine share similar
characteristics of hydropathy and polarity. Unfortunately, although genetic analysis of CIC03679,
unaffected son of CIC03678, revealed that he was not carrying p.(Asn956Lys), in absence of other
family members available for co-segregation analysis, its significance still remains unclear.
Variant c.3409A>G, p.(Arg1137Gly) carried by CIC03545, is predicted to be pathogenic by SIFT
and mutation taster although the residue was not conserved, being substituted by a Glutamine,
a Threonine or a Lysine in the conservation analysis (Table 1, Supplementary Table S2). However,
all these amino acids are polar while Glycine is not, hence an effect on the tridimensional structure of
the protein cannot be completely excluded.
Several hypomorphic alleles have been associated with STGD1 [27,29]. Even though many of them
were considered benign because of their high frequency, these alleles could be pathogenic when they
are in trans with severe variants, explaining many of the unsolved cases with only one or no mutations
detected on ABCA4 [27,29]. The presence of these alleles could help in classifying accompanying
ABCA4 mutations as severe mutations and in genotype-phenotype correlations.
For example, Zernant et al. [29] recently reported that the hypormophic variant p.(Asn1868Ile)
accounts for more than 50% of the missing causal alleles in monoallelic cases and about 80% of
late-onset cases and distinguishes ABCA4-related disease from AMD [29]. In our sub-cohort of
61 patients, this variant appeared in 14 subjects. Most of these cases presented p.(Asn1868Ile) in
cis with other disease causing mutations (12 subjects) and the phenotypes were typically consistent
with the effect of the overall genotype with mainly early onset and severe disease as documented
by Zernant et al. [29]. Only two subjects (CIC08283 and CIC04197) had p.(Asn1868Ile) alone, in trans
with other pathogenic variants, resulting in a milder phenotype. Further functional analysis should be
performed in order to confirm the pathogenicity of these variants.
Among the 63 patients carrying novel variants, we performed genotype-phenotype correlation
on 60 of them. The three subjects carrying a VUS were excluded from the analysis. According to
the genotype-phenotype model previously proposed [24], we observed an earlier age of onset and
more diffuse photoreceptor dysfunction (assessed by ff-ERGs) in NM group. These findings are in
accordance with the previous literature [12,52]. Regarding the peripapillary sparing, its loss was more
frequent in the NM group which is also associated with a higher prevalence of non-group I ff-ERG
consistent with previous publications reporting a loss of this sign in non-group I Stargardt disease [60].
Overall, in our group of 60 patients harboring novel likely pathogenic ABCA4 changes,
we observed a tendency for a worse phenotype when a truncating variant is present.
In this report we wanted to prioritize the characterization of the patients carrying novel variants.
Even though it is only a subgroup of subjects the results seem strong and consistent with previous
literature [12] and they probably reflect the genotype-phenotype correlation of the entire cohort.
Further analysis including a full clinical assessment of patients with known variants will be necessary
to confirm these findings.
However, even with a large cohort of patients, it is impossible to establish a precise
phenotype-genotype correlation only on the basis of the type of the mutation. In fact, two different
missense mutations involving residues at different location with distinct effects on the quaternary
structure of ABCA4 can produce very different phenotypes [12,61]. Nowadays, the main efforts
are aimed to find correlations between specific variants and clinical phenotype although the rarity
of many alleles makes this difficult. For this reason, we tried to provide an exhaustive clinical
characterization of each subject showing at least one novel mutation among the two mutant alleles of
ABCA4 (see Supplementary Table S3).
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4. Materials and Methods
Patients with a presumed diagnosis of STGD1 disease were recruited at the Reference Center for
rare diseases, Referet of the Quinze-Vingts hospital, Paris. Informed consent was obtained from each
patient after explanation of the study and its potential outcome. The study protocol adhered to the
tenets of the Declaration of Helsinki and was approved by a national ethics committee (CPP Ile de
France V, Project number 06693, N◦EUDRACT 2006-A00347-44, 11 December 2006). All the patients
and available family members were asked to donate a blood sample for genetic screening for ABCA4
mutations. Subjects with at least one novel variant were called back to undergo a complete phenotype
analysis as described below.
4.1. Mutation Analysis
Total genomic DNA was extracted from peripheral whole blood samples by standard salting
out procedures according to the manufacturer’s recommendation (Puregen Kit; Qiagen, Courtaboeuf,
France). The first consecutive 211 subjects were screened for known ABCA4 mutations by microarray
analysis on a commercially available microarray (ABCR600, ASPER Biotech, Inc., Tartu, Estonia) [48].
Among them, samples which were excluded for known variants were further investigated for variants
in the coding exons and their flanking regions of ABCA4 by PCR and direct Sanger sequencing.
The DNA of the other patients included in the study was directly sequenced by Sanger sequencing.
The 50 coding exons and flanking intronic regions were amplified in 48 fragments (ABCA4 RefSeq
NM_000350) using oligonucleotides reported in Supplementary Table S4, a commercially available
polymerase (HotFire, Solis Biodyne, Tartu, Estonia), 1.5 mM MgCl2 at an annealing temperature
of 58 ◦C for 1 min. The PCR products were enzymatically purified (ExoSAP-IT, USB Corporation,
Cleveland, OH, USA, purchased from GE Healthcare, Orsay, France) sequenced and investigated as
previously reported [62].
Nucleotide numbering reflects cDNA numbering with +1 corresponding to the A of the ATG
translation initiation codon in the reference sequence, according to journal guidelines (www.hgvs.org/
mutnomen).
All variants were classified following the American College of Medical Genetics and Genomics
(ACMG) standards and guidelines and the Association of Molecular Pathology (AMP) Clinical Practice
Guidelines and Reports based on previous publications (as compiled in the Human Gene Mutation
Database (HGMD) [63] and in the Leiden Open (source) Variation Database (LOVD) [64]), population
data, computational data and functional data. The Exome Aggregation Consortium (ExAC) database
was used to check variant frequency.
Novel variants with unknown frequency or minor allele frequency (MAF) ≤0.05 were further
tested using Alamut Visual software v. 2.7.1 where the in silico predictive programs PolyPhen2
(Polymorphism Phenotyping, http://genetics.bwh.harvard.edu/pph2/) [65], SIFT (Sorting Intolerant
from Tolerant; http://sift.bii.a-star.edu.sg/) [66], Mutation Taster (http://www.mutationtaster.
org/) [67] are implemented.
For splice site variants three different algorithms of prediction were used: MaxEntScan (http:
//genes.mit.edu/burgelab/maxent/Xmaxentscan_scoreseq.html) [68], NNSplice [69], and human
splicing finder v 3.0 (http://www.umd.be/HSF3/) [70].
Evolutionary conservation was investigated using the 46-way Vertebrate Multiz Alignment and
Conservation of the University of California Santa Cruz (UCSC) genome browser [71,72].
For missense mutations, an amino acid residue was considered highly conserved if the same
residue was present in all species or was different in just one species among fishes or reptiles,
moderately conserved if different in 2 to 5 species (included), and not conserved if different in
more than 5 species or in at least one primate.
A novel sequence variant was considered pathogenic if it represented a nonsense variant or small
insertion, deletion, or duplication inducing a frame-shift. In the case of a missense change, a novel
sequence variant was considered to be likely pathogenic if it was either predicted to be deleterious by
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all three prediction algorithms or if it affected a highly or moderately evolutionary conserved amino
acid residue and was predicted to be pathogenic by at least one algorithm mentioned above [73]. In all
other cases, a variant was classified as a VUS.
The same criteria described above, but considering DNA sequence, were applied to study the
conservation of nucleotide residues and pathogenicity of variants on putative or non-canonic splice
sites (±10 bases from exon boundaries).
4.2. Phenotypic Analysis
Patients with novel ABCA4 variants underwent full ophthalmic examination with assessment of
best corrected visual acuity (BCVA) with the Early Treatment Diabetic Retinopathy Study (ETDRS)
chart, kinetic and static perimetry, and color vision with the desaturated Farnsworth Panel D-15.
Full-field and multifocal electroretinography (ff-ERG and mf-ERG) were performed with DTL recording
electrodes and incorporated ISCEV Standards (Espion E2; for full field ERG; Diagnosys, Lowell, MA,
USA; and Veris II for multifocal ERG; EDI, Redwood City, CA, USA) [74,75]. Clinical assessment
was completed with color fundus photograph (FP; Topcon, Tokyo, Japan), short-wavelength fundus
autofluorescence (SW-AF), near-infrared fundus autofluorescence (NIR-AF), spectral domain optical
coherence tomography (SD-OCT; Heidelberg retina angiograph [HRA] II or Spectralis HRA+OCT;
Heidelberg Engineering, Dossenheim, Germany) after pupil dilatation with Tropicamide 1% and
phenylephrine 2.5%.
The phenotype was classified following all clinical criteria summarized in Table 3. Color fundus
photographs were acquired for each index patient and stratified in 4 groups according to a previously
described classification [54].
A confocal scanning laser ophthalmoscope (Heidelberg Retina Angiograph [HRA] II; Heidelberg
Engineering, Dossenheim, Germany) was used to acquire SW-AF images (488 nm excitation) and
NIR-AF images (787 nm excitation). Thanks to the eye-tracking function of the HRA and averaging
at least 30 single frames, 2 high-quality images (30◦ and 50◦ field of view respectively) for each
modality were taken for each eye. Subsequently, we divided patients into 5 groups according to
a previously described classification [55]: group 1: central lesion with jagged borders, group 2:
central lesion with extensive fundus changes; group 3: central lesion with smooth borders and an
hyperautofluorescent ring-like halo in SW-AF and NIR-AF; group 4: central lesion with smooth borders
and no hyperautofluorescent NIR-AF ring; group 5: small discrete central lesion better visualized
in NIR-AF. When RPE atrophy was present the measurement of the area was performed using
RegionFinder software (Heidelberg Engineering, Dossenheim, Germany; software version 2.5.8.0) on
SW-AF images [76]. The 50◦ images were used to establish the extension of fundus abnormalities and
for evaluating the peripapillary area [56].
A single horizontal high-resolution OCT B-Scan (9 mm) was obtained together with a
simultaneously acquired infra-red (IR) fundus image in a transverse plane through the fovea. This
image was used to evaluate the preservation of the ellipsoid zone (EZ) through the fovea [57] and the
possible foveal sparing from the disease [38]. A cube of OCT scans was then obtained in high-speed
mode with the automated real-time mode activated and set to 10 (creating a mean image of ten
repeated identical B-scans to improve signal-to-noise ratio). The cube scan protocol contains a density
of 49 B-scan lines covering an area of 20◦ × 20◦ centered on the fovea. As previously described,
a trained operator corrected any segmentation errors made by the software version with manual
segmentation [77,78]. When the quality of segmentation was adequate, the central retinal thickness
(CRT) and the total macular volume (TMV) were recorded and compared against the data of 30 normal
subjects (15 subjects younger than 30 years and 15 subjects older; Supplementary Table S5).
All patients underwent electrophysiological assessment, including ff-ERG and mf-ERG,
incorporating the minimum standards of the International Society for Clinical of Electrophysiology
of Vision (ISCEV) including the following stimulations: dark adapted dim flash 0.01 candela
second (cd·s/m2); dark-adapted bright flash 10.0 cd·s/m2; light adapted 3.0 cd·s/m2 30 Hz flicker
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ERG and light adapted 3.0 cd·s/m2 at 2 Hz. The patient data set were compared against those
of 30 healthy subjects (15 younger than 30 years old and 15 older; Supplementary Table S1). The limits
of ERG normality were defined for all the components of the ERG as the mean value ± 2 standard
deviations. All the components of the ERG from each eye were taken into account when classifying
patients into the three ERG groups defined by Lois et al. [53]: Group 1 has abnormal mf-ERG with
normal ff-ERG; in Group 2 there were mf-ERG abnormalities with cone dysfunction (assessed with
light-adapted 30 Hz flicker and light-adapted 3.0); Group 3 has additional rod dysfunction (assessed
using dark-adapted 0.01 and dark-adapted 10.0). The overall classification was based on the more
severe eye when the ERG group was different between eyes in the same patient.
4.3. Statistical Analysis
All data analysis was conducted using IBM SPSS Statistics software v. 21.0 (Chicago, IL, USA).
For BCVA, MV, and CRT we used the Wilcoxon signed-rank test to prove the agreement
between eyes.
Differences between the two genotype groups were analyzed using the Wilcoxon-Mann-Whitney
test for age of onset, age at visit, duration of the disease, BCVA, MV, and CRT. The Goodman-Kruskal
Gamma test was used to analyze the difference between NM and MM groups for fundus stage,
NIR-FAF, and IR-FAF groups, the presence of RPE atrophy, foveal sparing, peripapillary sparing, EZ
band integrity, and ERG group distribution. For these descriptive variants, when there was discordance
between the right and left eye, we considered the eye with the worse phenotype. A p value inferior to
0.05 was considered statistically significant.
5. Conclusions
Despite certain limitations in terms of detecting large CNVs (<1% of all disease-associated
alleles) [79] or mutations in non-coding regions, and the lack of functional analysis, our study broadens
the spectrum of ABCA4 mutations with 60 likely pathogenic or pathogenic variants, all associated
with STGD1.
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Abbreviations
MDPI Multidisciplinary Digital Publishing Institute
STGD-1 Stargardt disease-1
ABCA4 ATP-binding cassette, subfamily A, member 4
BCVA Best Corrected Visual Acuity
ff-ERG Full field electroretinography
mf-ERG Multi focal electroretinography
SW-AF Short-wavelength autofluorescence
NIR-AF Near-infrared Autofluorescence
SD-OCT Spectral Domain Optical Coherence Tomography
ISCEV International Society for Clinical of Electrophysiology of Vision
ACMG American College of Medical Genetics and Genomics
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AMP Association of Molecular Pathology
HGMD Human Gene Mutation Database
ExAC Exome Aggregation Consortium
PolyPhen2 Polymorphism Phenotyping
UCSC University of California Santa Cruz
SIFT Sorting intolerant from tolerant
RPE Retinal pigment epithelium
CRT Central retinal thickness
TMV Total macular volume
VUS Variant of uncertain significance
MAF Minor allele frequency
NGS Next-generation sequencing
WES Whole exome sequencing




MM At least one missense variant in the genotype
NM At least one null variant in the genotype
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Szaflik, J.; Szaflik, J.P.; Płoski, R.; et al. Next-generation sequencing of ABCA4: High frequency of complex
alleles and novel mutations in patients with retinal dystrophies from Central Europe. Exp. Eye Res. 2016, 145,
93–99. [CrossRef] [PubMed]
59. Zaneveld, J.; Siddiqui, S.; Li, H.; Wang, X.; Wang, H.; Wang, K.; Li, H.; Ren, H.; Lopez, I.; Dorfman, A.; et al.
Comprehensive analysis of patients with Stargardt macular dystrophy reveals new genotype-phenotype
correlations and unexpected diagnostic revisions. Genet. Med. 2015, 17, 262–270. [CrossRef] [PubMed]
60. Burke, T.R.; Allikmets, R.; Smith, R.T.; Gouras, P.; Tsang, S.H. Loss of peripapillary sparing in non-group I
Stargardt disease. Exp. Eye Res. 2010, 91, 592–600. [CrossRef] [PubMed]
61. Ahn, J.; Beharry, S.; Molday, L.L.; Molday, R.S. Functional interaction between the two halves of the
photoreceptor-specific ATP binding cassette protein ABCR (ABCA4). Evidence for a non-exchangeable ADP
in the first nucleotide binding domain. J. Biol. Chem. 2003, 278, 39600–39608. [CrossRef] [PubMed]
62. Audo, I.; Manes, G.; Mohand-Saïd, S.; Friedrich, A.; Lancelot, M.-E.; Antonio, A.; Moskova-Doumanova, V.;
Poch, O.; Zanlonghi, X.; Hamel, C.P.; et al. Spectrum of rhodopsin mutations in French autosomal dominant
rod-cone dystrophy patients. Investig. Ophthalmol. Vis. Sci. 2010, 51, 3687–3700. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2018, 19, 2196 27 of 27
63. Stenson, P.D.; Ball, E.V.; Mort, M.; Phillips, A.D.; Shiel, J.A.; Thomas, N.S.T.; Abeysinghe, S.; Krawczak, M.;
Cooper, D.N. Human Gene Mutation Database (HGMD): 2003 update. Hum. Mutat. 2003, 21, 577–581.
[CrossRef] [PubMed]
64. Fokkema, I.F.A.C.; Taschner, P.E.M.; Schaafsma, G.C.P.; Celli, J.; Laros, J.F.J.; den Dunnen, J.T. LOVD v.2.0:
The next generation in gene variant databases. Hum. Mutat. 2011, 32, 557–563. [CrossRef] [PubMed]
65. Adzhubei, I.A.; Schmidt, S.; Peshkin, L.; Ramensky, V.E.; Gerasimova, A.; Bork, P.; Kondrashov, A.S.;
Sunyaev, S.R. A method and server for predicting damaging missense mutations. Nat. Methods 2010, 7,
248–249. [CrossRef] [PubMed]
66. Sim, N.-L.; Kumar, P.; Hu, J.; Henikoff, S.; Schneider, G.; Ng, P.C. SIFT web server: Predicting effects of amino
acid substitutions on proteins. Nucleic Acids Res. 2012, 40, W452–W457. [CrossRef] [PubMed]
67. Schwarz, J.M.; Cooper, D.N.; Schuelke, M.; Seelow, D. MutationTaster2: Mutation prediction for the
deep-sequencing age. Nat. Methods 2014, 11, 361–362. [CrossRef] [PubMed]
68. Yeo, G.; Burge, C.B. Maximum entropy modeling of short sequence motifs with applications to RNA splicing
signals. J. Comput. Biol. 2004, 11, 377–394. [CrossRef] [PubMed]
69. Reese, M.G.; Eeckman, F.H.; Kulp, D.; Haussler, D. Improved splice site detection in Genie. J. Comput. Biol.
1997, 4, 311–323. [CrossRef] [PubMed]
70. Desmet, F.-O.; Hamroun, D.; Lalande, M.; Collod-Béroud, G.; Claustres, M.; Béroud, C. Human Splicing
Finder: An online bioinformatics tool to predict splicing signals. Nucleic Acids Res. 2009, 37, e67. [CrossRef]
[PubMed]
71. Casper, J.; Zweig, A.S.; Villarreal, C.; Tyner, C.; Speir, M.L.; Rosenbloom, K.R.; Raney, B.J.; Lee, C.M.; Lee, B.T.;
Karolchik, D.; et al. The UCSC Genome Browser database: 2018 update. Nucleic Acids Res. 2017. [CrossRef]
72. Kent, W.J. BLAT—The BLAST-like alignment tool. Genome Res. 2002, 12, 656–664. [CrossRef] [PubMed]
73. Richards, S.; Aziz, N.; Bale, S.; Bick, D.; Das, S.; Gastier-Foster, J.; Grody, W.W.; Hegde, M.; Lyon, E.;
Spector, E.; et al. Standards and guidelines for the interpretation of sequence variants: A joint consensus
recommendation of the American College of Medical Genetics and Genomics and the Association for
Molecular Pathology. Genet. Med. 2015, 17, 405–424. [CrossRef] [PubMed]
74. Marmor, M.F.; Fulton, A.B.; Holder, G.E.; Miyake, Y.; Brigell, M.; Bach, M.; International Society for Clinical
Electrophysiology of Vision. ISCEV Standard for full-field clinical electroretinography (2008 update).
Doc. Ophthalmol. 2009, 118, 69–77. [CrossRef] [PubMed]
75. Hood, D.C.; Bach, M.; Brigell, M.; Keating, D.; Kondo, M.; Lyons, J.S.; Palmowski-Wolfe, A.M. ISCEV
guidelines for clinical multifocal electroretinography (2007 edition). Doc. Ophthalmol. 2008, 116, 1–11.
[CrossRef] [PubMed]
76. Schmitz-Valckenberg, S.; Brinkmann, C.K.; Alten, F.; Herrmann, P.; Stratmann, N.K.; Göbel, A.P.;
Fleckenstein, M.; Diller, M.; Jaffe, G.J.; Holz, F.G. Semiautomated image processing method for identification
and quantification of geographic atrophy in age-related macular degeneration. Investig. Ophthalmol. Vis. Sci.
2011, 52, 7640–7646. [CrossRef] [PubMed]
77. Strauss, R.W.; Muñoz, B.; Wolfson, Y.; Sophie, R.; Fletcher, E.; Bittencourt, M.G.; Scholl, H.P.N. Assessment
of estimated retinal atrophy progression in Stargardt macular dystrophy using spectral-domain optical
coherence tomography. Br. J. Ophthalmol. 2016, 100, 956–962. [CrossRef] [PubMed]
78. Parker, M.A.; Choi, D.; Erker, L.R.; Pennesi, M.E.; Yang, P.; Chegarnov, E.N.; Steinkamp, P.N.; Schlechter, C.L.;
Dhaenens, C.-M.; Mohand-Said, S.; et al. Test-Retest Variability of Functional and Structural Parameters in
Patients with Stargardt Disease Participating in the SAR422459 Gene Therapy Trial. Transl. Vis. Sci. Technol.
2016, 5, 10. [CrossRef] [PubMed]
79. Lee, W.; Xie, Y.; Zernant, J.; Yuan, B.; Bearelly, S.; Tsang, S.H.; Lupski, J.R.; Allikmets, R. Complex inheritance
of ABCA4 disease: Four mutations in a family with multiple macular phenotypes. Hum. Genet. 2016, 135,
9–19. [CrossRef] [PubMed]
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
